Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Sees Significant Increase in Short Interest

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) was the recipient of a large growth in short interest during the month of January. As of January 15th, there was short interest totalling 6,000,000 shares, a growth of 6.0% from the December 31st total of 5,660,000 shares. Based on an average daily volume of 250,800 shares, the days-to-cover ratio is currently 23.9 days. Approximately 31.2% of the company’s stock are short sold.

Hedge Funds Weigh In On Dianthus Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Janus Henderson Group PLC lifted its stake in Dianthus Therapeutics by 40.5% during the 3rd quarter. Janus Henderson Group PLC now owns 949,334 shares of the company’s stock valued at $25,936,000 after acquiring an additional 273,670 shares during the period. State Street Corp lifted its position in Dianthus Therapeutics by 101.4% during the third quarter. State Street Corp now owns 821,131 shares of the company’s stock valued at $22,483,000 after purchasing an additional 413,425 shares during the period. Braidwell LP lifted its position in Dianthus Therapeutics by 34.6% during the third quarter. Braidwell LP now owns 493,687 shares of the company’s stock valued at $13,517,000 after purchasing an additional 126,836 shares during the period. Point72 Asset Management L.P. boosted its holdings in Dianthus Therapeutics by 151.3% in the third quarter. Point72 Asset Management L.P. now owns 437,700 shares of the company’s stock valued at $11,984,000 after purchasing an additional 263,500 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in Dianthus Therapeutics by 142.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 165,929 shares of the company’s stock worth $4,543,000 after purchasing an additional 97,362 shares during the period. Institutional investors and hedge funds own 47.53% of the company’s stock.

Dianthus Therapeutics Price Performance

Shares of DNTH opened at $22.15 on Monday. The company’s fifty day moving average price is $23.12 and its 200-day moving average price is $25.94. Dianthus Therapeutics has a 1-year low of $18.00 and a 1-year high of $33.77. The firm has a market capitalization of $655.64 million, a PE ratio of -8.86 and a beta of 1.74.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.15). Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The firm had revenue of $2.17 million for the quarter, compared to analysts’ expectations of $1.07 million. As a group, research analysts anticipate that Dianthus Therapeutics will post -2.61 EPS for the current fiscal year.

Analyst Ratings Changes

DNTH has been the topic of a number of recent analyst reports. Oppenheimer raised their price target on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the company an “outperform” rating in a report on Monday, November 11th. HC Wainwright restated a “buy” rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a research note on Monday, November 11th. Raymond James raised Dianthus Therapeutics to a “moderate buy” rating in a research report on Thursday, December 12th. Finally, TD Cowen began coverage on Dianthus Therapeutics in a research report on Friday, December 20th. They issued a “buy” rating for the company. Eight research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $46.43.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.